Clinical trials: Hyperlipemia
Hyperlipemia, Mixed, ASCVD
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management
A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values.
- Trial name
- LDL-ALERT (NCT05088759)
- Testing
- Alert
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Cardiovascular, Metabolic Disease
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
- Conditions
- Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder
- Trial name
- NCT07491172
- Testing
- CTX310
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- CRISPR Therapeutics AG
Familial Hypercholesterolemia, Familial Hypercholesterolemia Due to Genetic Defect of Apolipoprotein B
Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia
ACCURATE will test the hypothesis that opportunistic genetic testing for Familial Hypercholesterolemia (FH) in patients admitted to hospital with an acute coronary syndrome will increase the diagnosis of FH and will impact…
- Conditions
- Familial Hypercholesterolemia, Familial Hypercholesterolemia Due to Genetic Defect of Apolipoprotein B, Familial Hypercholesterolemia Due to Heterozygous LDL Receptor Mutation, Familial Hypercholesterolemia - Heterozygous
- Trial name
- ACCURATE (NCT05218005)
- Testing
- Research-based genetic test for Familial Hypercholesterolemia
- Where
- 2 sites in Canada
- Volunteers
- 140 people
- Sponsor
- University of British Columbia
Hyperlipemia
A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022
This is a randomized, single blind, placebo controlled, single center phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of subcutaneously…
- Trial name
- NCT05912296
- Testing
- RBD7022
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Suzhou Ribo Life Science Co. Ltd.
Hyperlipemia
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2053 when administered subcutaneously to subjects with normal and elevated LDL-C.
- Trial name
- NCT06229548
- Testing
- SYH2053
- Where
- China
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1
Genetic Testing and Motivational Counseling for FH
To date, there are highly effective lipid-lowering drugs, the combination of which makes it possible to achieve the target level of LDL-C in most patients with familial hypercholesterolemia (FH).
- Conditions
- Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2, Hypercholesterolemia, Familial, 3
- Trial name
- GENMOTIV-FH (NCT04656028)
- Testing
- Genetic Testing, Motivational Counseling, Lipid analysis
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Cardiovascular Disease (CVD), Hypertension
Veteran Peer Coaches Optimizing and Advancing Cardiac Health
The purpose of this study is to test if having a Veteran peer health coach will improve blood pressure control among Veterans with high blood pressure and at least one other Cardiovascular disease (CVD) risk factor.
- Conditions
- Cardiovascular Disease (CVD), Hypertension, Hyperlipemia, Obesity
- Trial name
- Vet-COACH (NCT02697422)
- Testing
- Community-based peer health coach intervention
- Where
- United States
- Volunteers
- 264 people
- Sponsor
- VA Office of Research and Development
Hyperlipemia
To Evaluate the Efficacy and Safety of JS002 in HoFH Patients
JS002 is a recombinant human anti-PCSK9 monoclonal antibody. This phase II open-label, single-arm study aims to evaluate the efficacy and safety of JS002 in patients with homozygous familial hypercholesterolemia A dose group (450…
- Trial name
- NCT04515927
- Testing
- JS002
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hyperlipemia, Hypertension
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
This is a randomized pilot trial to examine the feasibility, acceptability, and preliminary efficacy of an adaptive text message intervention (TMI) to promote well-being and health behavior adherence in 60 patients with two or…
- Conditions
- Hyperlipemia, Hypertension, Type2 Diabetes
- Trial name
- NCT04382521
- Testing
- Text Message Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Massachusetts General Hospital
Hyperlipemia
Safety and Tolerability of SHR-1918 in Healthy Subjects
The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918…
- Trial name
- NCT05432544
- Testing
- SHR-1918
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Primary Hypercholesterolemia, Mixed Hyperlipemia
Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage
The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia and hyperlipemia.
- Trial name
- NCT04849000
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 709 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hyperlipemia
The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy, as well as immunogenicity of JS002 treated repeatedly in patients…
- Trial name
- NCT04781114
- Testing
- JS002
- Where
- 57 sites in China
- Volunteers
- 806 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hyperlipemia
The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of JS002 prefilled syringes and prefilled autosyringes in patients…
- Trial name
- NCT05532800
- Testing
- JS002
- Where
- 21 sites in China
- Volunteers
- 255 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hyperlipemia
Effect of Consumption of Bagel Without Palm Oil on Postprandial Lipidemia
Postprandial lipemia produced by fat intake is a major risk factor for the development of cardiovascular diseases (CVD), the most important cause of disease and death in the Western world.
- Trial name
- PALMFREE (NCT03950752)
- Testing
- Optimized Bagel, Conventional Bagel
- Where
- Spain
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Technological Centre of Nutrition and Health, Spain
Hyperlipemia, Mixed
Study to Evaluate the Safety and PK of UI018
This Study is to evaluate the safety and pharmacokinetics of a fixed dose combination formulation and co-administration.
- Trial name
- NCT05085184
- Testing
- administration of UI018, co-administration of UIC201806 and UIC201602
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Hyperlipemia
A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody.
- Trial name
- NCT04469673
- Testing
- Biological：JS002
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hyperlipemia, Carbohydrate Inducible
Milk as a Recovery Beverage After Exercise for Improving Metabolic Health
Fasting blood fat levels (triglycerides) are often used to assess risk of heart disease but the level of fats in the blood after a meal is actually a stronger risk factor.
- Trial name
- NCT03154216
- Testing
- Exercise, Drink
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Sedentary Lifestyle, Dyslipidemias
Effects of Exercise on Fructose-induced Postprandial Lipemia
Cardiovascular Diseases (CVDs) are the leading causes of death in the world and in Brazil. In 2001, 12.45 million deaths on the globe (21% of the total) were caused by some CVD.
- Conditions
- Sedentary Lifestyle, Dyslipidemias, Lipid Metabolism Disorders, Carbohydrate Inducible Hyperlipemia
- Trial name
- NCT03173495
- Testing
- FRUCTOSE, DEXTROSE, EXERCISE
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Federal University of Rio Grande do Sul
Hyperlipemia, Coronary Heart Disease
Effect of Rosuvastatin Therapy on HDL2 Level
In many large trials, reducing low density lipoprotein (LDL) levels with rosuvastatin decreased the incidence of major cardiovascular events，but little attention to the effects of rosuvastatin on HDL level，especially on HDL…
- Trial name
- NCT02593487
- Testing
- Rosuvastatin 10mg/d group, Rosuvastatin 20mg/d group
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Hypercholesterolemia, Mixed Hyperlipemia
MK0859 Dose-Ranging Study (0859-003)
To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- NCT00325455
- Testing
- MK0859
- Volunteers
- 500 people
- Sponsor
- Merck Sharp & Dohme LLC